

LITERATURA

1. Gensollen T, Lyer SS, Kasper DL, et al. How colonization by microbiota in early life shapes the immune system. *Science*. 2016;352(6285):539-544.
2. Guentzel MN. *Escherichia*, *Klebsiella*, *Enterobacter*, *Serratia*, *Citrobacter*, and *Proteus*. In: Baron S, editor. *Medical Microbiology*. 4<sup>th</sup> edition. Galveston (TX): University of Texas Medical Branch at Galveston. 1996. Chapter 26.
3. Baldelli V, Scaldaferrì F, Putignani L, et al. The Role of Enterobacteriaceae in Gut Microbiota Dysbiosis in Inflammatory Bowel Diseases. *Microorganisms*. 2021;9(4):697.
4. Seenivasan B, RM Saravana K, Snega Priya P, et al. Gut Enterobacteriaceae and uraemic toxins - Perpetrators for ageing. *Experimental Gerontology*. 2023;173:112088.
5. Scheperjans F, Aho V, Pereira PA, et al. Gut microbiota are related to Parkinson's disease and clinical phenotype. *Mov Disord*. 2015;30(3):350-358.
6. De Angelis M, Piccolo M, Vannini L, et al. Fecal microbiota and metabolome of children with autism and pervasive developmental disorder not otherwise specified. *PLoS One*. 2013;8(10):e76993.
7. Hernandez-Alonso E, Bourgeois-Nicolaos N, Lepointeur M, et al. Contaminated Incubators: Source of a Multispecies Enterobacter Outbreak of Neonatal Sepsis. *Microbiol Spectr*. 2022;10(4):e0096422.
8. Matamoros S, Gras-Leguen C, Le Vacon F, et al. Development of intestinal microbiota in infants and its impact on health. *Trends Microbiol*. 2013;21(4):167-173.
9. Zhong H, Penders J, Shi Z, et al. Impact of early events and lifestyle on the gut microbiota and metabolic phenotypes in young school-age children. *Microbiome*. 2019;7(1):2.
10. Neu J, Rushing J. Cesarean versus vaginal delivery: long-term infant outcomes and the hygiene hypothesis. *Clin Perinatol*. 2011;38(2):321-331.
11. Arrieta MC, Stiemsma LT, Amenyogbe N, et al. The intestinal microbiome in early life: health and disease. *Front Immunol*. 2014;5:427.
12. Octavia S, Lan R. The Family Enterobacteriaceae. In: Rosenberg E, DeLong EF, Lory S, et al. (editors) *The Prokaryotes*. Springer, Berlin, Heidelberg. 2014.
13. Roux B, Walsh CT. p-aminobenzoate synthesis in *Escherichia coli*: kinetic and mechanistic characterization of the amidotransferase PabA. *Biochemistry*. 1992;31(30):6904-6910.
14. Patel A, Singhania R, Pandey E, et al. Enterobacteriaceae, coliforms and *E. coli* Introduction, Batt C, Tortorello M. (editors), *Encyclopedia of Food Microbiology (Second Edition)*, Academic Press. 2014: 659-666.
15. Stewart V. Regulation of nitrate and nitrite reductase synthesis in enterobacteria. *Antonie Van Leeuwenhoek*. 1994;66(1-3):37-45.
16. Pradhan S, Weiss AA. Probiotic Properties of *Escherichia coli* Nissle in Human Intestinal Organoids. *mBio*. 2020;11(4):e01470-20.
17. Melville JM, Moss TJ. The immune consequences of preterm birth. *Front Neurosci*. 2013;7:79.
18. Stewart C, Marris E, Nelson A, et al. Development of the Preterm Gut Microbiome in Twins at Risk of Necrotizing Enterocolitis and Sepsis. *PLoS ONE*. 2013;8(8):e73465.
19. Hill CJ, Lynch DB, Murphy K, et al. Evolution of gut microbiota composition from birth to 24 weeks in the INFANTMET Cohort. *Microbiome* 5. 2017.
20. McClure P. 10 – *Escherichia coli*: virulence, stress response and resistance. In Woodhead Publishing Series in Food Science, Technology and Nutrition, Understanding Pathogen Behaviour, Woodhead Publishing. 2005:240-278.
21. Nathan C, Cunningham-Bussel A. Beyond oxidative stress: an immunologist's guide to reactive oxygen species. *Nat Rev Immunol* 13. 2013:349-361.
22. Taylor WI, Achanzar D. Catalase test as an aid to the identification of Enterobacteriaceae. *Appl Microbiol*. 1972;24(1):58-61.
23. Gough D, Cotter T. Hydrogen peroxide: a Jekyll and Hyde signalling molecule. *Cell Death Dis* 2. 2011: e213.
24. Iredell J, Brown J, Tagg K. Antibiotic resistance in Enterobacteriaceae: mechanisms and clinical implications. *BMJ*. 2016;352:h6420.
25. Davin-Regli A, Lavigne JP, Pagès JM. Enterobacter spp.: Update on Taxonomy, Clinical Aspects, and Emerging Antimicrobial Resistance. *Clin Microbiol Rev*. 2019;32(4):e00002-19.
26. Girlich D, Ouzani S, Emerald C, et al. Uncovering the novel Enterobacter cloacae complex species responsible for septic shock deaths in newborns: a cohort study. *Lancet Microbe*. 2021;2(10):e536-e544.
27. Kaper JB, Nataro J, Mobley H. Pathogenic *Escherichia coli*. *Nat Rev Microbiol* 2. 2004:123-140
28. Nataro JP, Kaper JB. Diarrheagenic *Escherichia coli*. *Clin Microbiol Rev* 11. 1998.
29. Geurtsen J, de Been M, Weerdenburg E, et al. Genomics and pathotypes of the many faces of *Escherichia coli*. *FEMS Microbiol Rev*. 2022;46(6):fuac031.
30. Rousseaux A, Brosseau C, Le Gall S, et al. Human Milk Oligosaccharides: Their Effects on the Host and Their Potential as Therapeutic Agents. *Front Immunol*. 2021;12:680911.
31. Baud O, Aujard Y. Neonatal bacterial meningitis. *Handb Clin Neurol*. 2013;112:1109-1113.
32. Poolman JT, Wacker M. Extraintestinal Pathogenic *Escherichia coli*, a Common Human Pathogen: Challenges for Vaccine Development and Progress in the Field. *J Infect Dis*. 2016;213(1):6-13.
33. Fu J, Li L, Huo D, et al. Meningitic *Escherichia coli*  $\alpha$ -hemolysin aggravates blood-brain barrier disruption via targeting TGF $\beta$ 1-triggered hedgehog signaling. *Mol Brain*. 2021;14(1):116.
34. Helena De Oliveira L, Jauregui B, Carvalho AF, et al. Impact and effectiveness of meningococcal vaccines: a review. *Rev Panam Salud Publica*. 2017;41:e158.
35. Dekker JP, Frank KM. Salmonella, Shigella, and yersinia. *Clin Lab Med*. 2015;35(2):225-246.
36. Peterson JW. Bacterial Pathogenesis. In: Baron S, editor. *Medical Microbiology*. 4<sup>th</sup> edition. Galveston (TX): University of Texas Medical Branch at Galveston. 1996. Chapter 7.
37. Abbas R, Chakkour M, Zein El Dine H, et al. General Overview of *Klebsiella pneumoniae*: Epidemiology and the Role of Siderophores in Its Pathogenicity. *Biology*. 2024;13(2):78.
38. Murphy CN, Clegg S. *Klebsiella pneumoniae* and type 3 fimbriae: nosocomial infection, regulation and biofilm formation. *Future Microbiol*. 2012;7(8):991-1002.
39. Samonis G, Karageorgopoulos D, Kofteridis D, et al. Citrobacter infections in a general hospital: Characteristics and outcomes. *European journal of clinical microbiology & infectious diseases*. 2008;28:61-68.
40. Ekundayo TC, Ijabadeniyi OA. Global and regional prevalence of *Cronobacter sakazakii* in powdered milk and flour. *Sci Rep* 14. 2024:6865.
41. Healy B, Cooney S, O'Brien S, et al. *Cronobacter* (Enterobacter sakazakii): an opportunistic food-borne pathogen. *Foodborne Pathog Dis*. 2010;7(4):339-350.
42. World Health Organization. Strengthening health systems to improve health outcomes: WHO's framework for action. 2007. [https://iris.who.int/bitstream/handle/10665/44032/9789241563796\\_eng.pdf?sequence=1](https://iris.who.int/bitstream/handle/10665/44032/9789241563796_eng.pdf?sequence=1). Cited 4 July 2024.
43. Dunn AB, Jordan S, Baker BJ, et al. The Maternal Infant Microbiome: Considerations for Labor and Birth. *MCN Am J Matern Child Nurs*. 2017;42(6):318-325.
44. Mueller NT, Differding MK, Sun H, et al. Maternal Bacterial Engraftment in Multiple Body Sites of Cesarean Section Born Neonates after Vaginal Seeding-a Randomized Controlled Trial. *mBio*. 2023;14(3):e0049123.
45. O'Sullivan A, Farver M, Smilowitz JT. The Influence of Early Infant-Feeding Practices on the Intestinal Microbiome and Body Composition in Infants. *Nutr Metab Insights*. 2015;8(Suppl 1):1-9.
46. Abdelhamid AG, El-Masry SS, El-DougDoug NK. Probiotic *Lactobacillus* and *Bifidobacterium* strains possess safety characteristics, antiviral activities and host adherence factors revealed by genome mining. *EPMA J*. 2019;10(4):337-350.
47. Aleman RS, Yadav A. Systematic Review of Probiotics and Their Potential for Developing Functional Nondairy Foods. *Applied Microbiology*. 2024;4(1):47-69.
48. Hung YP, Lee CC, Lee JC, et al. The Potential of Probiotics to Eradicate Gut Carriage of Pathogenic or Antimicrobial-Resistant Enterobacterales. *Antibiotics*. 2021;10(9):1086.
49. Cukrowska B, Ladinová-Zádníková R, Enders C, et al. Specific proliferative and antibody responses of premature infants to intestinal colonization with nonpathogenic probiotic *E. coli* strain Nissle 1917. *Scand J Immunol*. 2002;55(2):204-209.
50. World Health Organization. Antimicrobial resistance and primary health care. 2018. <https://www.who.int/docs/default-source/primary-health-care-conference/amr.pdf> Cited July 4, 2024.
51. Dawczynski K, Proquitté H, Roedel J, et al. Intensified colonisation screening according to the recommendations of the German Commission for Hospital Hygiene and Infectious Diseases Prevention (KRINKO): identification and containment of a *Serratia marcescens* outbreak in the neonatal intensive care unit, Jena, Germany, 2013–2014. *Infection*. 2016;44(6):739-746.